Display Settings:

Format

Send to:

Choose Destination
    Altern Ther Health Med. 2009 Mar-Apr;15(2):42-6.

    Relative bioavailability comparison of different coenzyme Q10 formulations with a novel delivery system.

    Source

    GeroNutra, Hayward, California, USA.

    Abstract

    Commercial coenzyme Q10 (CoQ10, ubiquinone) formulations are often of poor intestinal absorption. The relative bioavailability of CoQ10 has been shown in National Institutes of Health-funded clinical trials to be increased by its delivery system. We investigated the bioavailability of a new CoQ10 formulation based on a new and patented technology, VESIsorb, with 3 other commercially available CoQ10 products, an oil-based formulation and 2 solubilizates. This new CoQ10 formulation (commercially branded CoQsource) is a lipid-based formulation that naturally self-assembles on contact with an aqueous phase into an association colloid delivery system (hereafter "colloidal-Q10"). Twenty healthy male and female subjects participated in a double-blind, comparative (parallel design), controlled, single-dose (120 mg) bioavailability study. Plasma concentration of CoQ10 was determined at baseline and at various intervals after administration over a 24-hour period. To compare bioavailability, maximum concentration (Cmax) and area under curve from 0 to 10 hours (AUC(0-10h)) were assessed. The kinetic profiles of all CoQ10 preparations revealed a 1-peak plasma concentration-time course. Highest Cmax values were seen after colloidal-Q10 administration. Colloidal-Q10 not only had the highest plasma concentration levels after 1 hour, but it continued to increase before reaching Cmax at about 4 hours. The plasma concentration of colloidal-Q10 remained well above the levels of the 3 other products throughout the 24-hour period. The relative bioavailability calculated using the AUC(0-10h) values was also the highest for colloidal-Q10; the AUC(0-10h) values were 30.6, 6.1, 4.9, and 10.7 microg/mL*h for colloidal-Q10, solubilizate 1, the oil-based formulation, and solubilizate 2, respectively. Differences in Cmax and AUC between colloidal-Q10 and the 3 other formulations were statistically significant. In summary, the data presented suggests that colloidal-Q10 improves the enteral absorption and the bioavailability of CoQ10 in humans.

    PMID:
    19284181
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk